It could be an equalizer, but only if they can reach it
In early December 2023, the FDA crossed a threshold that scientists and patients have long anticipated: approving the first gene-editing therapies ever cleared for human use, both aimed at sickle cell disease, a condition that has quietly diminished the lives of roughly 100,000 Americans, most of them Black. The treatments, Casgevy and Lyfgenia, do not merely manage the disease — they reach into the genetic source of suffering and attempt to correct it. Yet as medicine advances, it raises the enduring question of whether healing belongs equally to all, or only to those with the means to reach it.
- For generations, sickle cell patients have endured days-long pain crises as misshapen blood cells choke off oxygen — a disease that has derailed careers, relationships, and the ordinary rhythm of life.
- The FDA's approval of Casgevy and Lyfgenia marks the first time gene-editing technology has been cleared for use in any human disease, a scientific milestone decades in the making.
- Both therapies extract a patient's own stem cells, edit them in a laboratory — one using CRISPR directly, the other deploying a gene delivery vehicle — and return them to the body to prevent sickling at its source.
- Early recipients like Jennelle Stephenson, treated before approval in 2017, describe the results as transformative, providing the real-world evidence that anchored the FDA's historic decision.
- Despite the breakthrough, multi-million dollar price tags and a limited number of authorized treatment centers threaten to keep the cure out of reach for the very communities most burdened by the disease.
On a Friday in early December, the FDA approved two therapies — Casgevy and Lyfgenia — that mark the first time gene-editing treatments have ever been cleared for human use. Both target sickle cell disease, a blood disorder affecting roughly 100,000 Americans, predominantly Black Americans and Hispanics, in which a mutation causes red blood cells to warp into a sickle shape, jamming blood vessels and triggering episodes of severe pain that can upend every dimension of a person's life.
The two therapies take different technical routes to the same destination. Casgevy uses CRISPR to correct the underlying mutation in a patient's own blood stem cells. Lyfgenia uses a gene delivery vehicle to alter stem cells so they produce a modified hemoglobin that prevents sickling. In both cases, cells are extracted, edited in a laboratory, and returned to the patient's body. FDA officials called the moment a watershed, noting that gene therapy holds particular promise for rare diseases where existing options have fallen short.
The human evidence behind the approval is real. Jennelle Stephenson of Cleveland, Tennessee received gene therapy for sickle cell in 2017, years before any formal clearance. After a life defined by relentless pain crises, the treatment changed everything. 'It's been one incredible journey of success for me,' she said — and her experience, alongside others, formed the foundation for the FDA's decision.
President Biden marked the approval as a testament to what government-backed scientific ambition can achieve, and suggested these therapies might open doors to treatments for other rare diseases. But the harder question is already in view. The therapies cost millions of dollars, and only a handful of authorized medical centers can administer them. Experts like Dr. Rabi Hanna of the Cleveland Clinic see the potential for these treatments to be an equalizer — but only if patients can actually reach them. The science has arrived. Whether the systems meant to deliver it can keep pace remains unresolved.
On a Friday in early December, the Food and Drug Administration cleared two treatments that represent a threshold moment in medicine: the first human gene-editing therapies ever approved for use. Both target sickle cell disease, a blood disorder that affects roughly 100,000 Americans, predominantly Black Americans and Hispanics.
The two therapies are called Casgevy and Lyfgenia. They work through different mechanisms but share the same goal: to fix the genetic mistake that causes sickle cell disease in the first place. The disease stems from a mutation in hemoglobin, the protein inside red blood cells responsible for carrying oxygen throughout the body. When hemoglobin is malformed, the red blood cells themselves warp into a sickle shape. These twisted cells jam up in blood vessels, choking off oxygen flow and triggering episodes of severe pain that can last for days. The disease disrupts careers, education, relationships—the ordinary architecture of a life.
Casgevy uses CRISPR, the gene-editing technology that has animated scientific hope and ethical debate for years. It modifies a patient's own blood stem cells, correcting the mutation at its source. Lyfgenia takes a different path, using a gene delivery vehicle to alter stem cells so they produce a modified hemoglobin that prevents the sickling process. Both are cell-based therapies, meaning doctors extract cells from the patient, edit them in the laboratory, and return them to the body to do their work.
Dr. Nicole Verdun, speaking for the FDA, framed the approval as a watershed. "Gene therapy holds the promise of delivering more targeted and effective treatments, especially for individuals with rare diseases where the current treatment options are limited," she said. Her colleague Dr. Peter Marks called it "an important medical advance with the use of innovative cell-based gene therapies to target potentially devastating diseases."
But approval and access are not the same thing. The therapies carry price tags in the millions of dollars. Only a limited number of medical centers across the country are authorized to administer them. The result is a gap between what medicine can now do and what medicine can actually deliver to the people who need it most. Experts acknowledge the tension plainly. Dr. Rabi Hanna of the Cleveland Clinic said the therapies "could be an equalizer for people with sickle cell because many patients cannot pursue career options" due to the illness—but only if they can actually reach the treatment.
Jennelle Stephenson of Cleveland, Tennessee was among the first to receive gene therapy for sickle cell disease, back in 2017, before FDA approval. She had endured the relentless pain episodes that define the disease. After treatment, the change was decisive. "It's been one incredible journey of success for me," she said. Her experience, and others like it, provided the evidence base for the FDA's decision.
President Biden released a statement late Friday, situating the approval within a larger narrative about American innovation and government investment. He noted that when the federal government backs scientific ambition, breakthroughs become possible. He also gestured toward the broader horizon: these two approvals, he suggested, might open pathways to treatments for other rare diseases that have so far resisted cure.
What happens next depends partly on whether the barriers to access can be dismantled. The science has moved forward. The question now is whether the infrastructure—the funding, the facilities, the logistics of getting patients to treatment—can keep pace.
Citações Notáveis
Gene therapy holds the promise of delivering more targeted and effective treatments, especially for individuals with rare diseases where current treatment options are limited.— Dr. Nicole Verdun, FDA
It's been one incredible journey of success for me.— Jennelle Stephenson, first gene therapy patient
A Conversa do Hearth Outra perspectiva sobre a história
Why does it matter that this is the first approved gene-editing therapy, rather than just another new drug?
Because it's not treating the symptom. It's rewriting the instruction manual. Every cell in your body is a copy of the original mistake. This therapy goes back to the source code and fixes it.
So the patient is cured, not just managed?
In the cases we've seen so far, yes. The pain episodes stop. The disease doesn't come back. But we're still learning the long-term picture. This is new territory.
You mentioned access barriers. How real is that problem?
Very real. These therapies cost millions. A handful of hospitals can do them. If you live in a rural area, or you don't have insurance that covers it, or you can't take months off work for treatment, you're locked out. The FDA approved it for 100,000 people, but only a fraction will actually get it.
Is there a path to making it cheaper or more available?
That's the open question. As more facilities get trained, as competition increases, costs might fall. But right now, the infrastructure just isn't there. It's a bottleneck.
What does Jennelle Stephenson's experience tell us?
That it works. That the pain can actually stop. That's not theoretical—that's a person whose life changed. But she was part of a trial. Most people with sickle cell won't have that opportunity, at least not yet.